Histrelin Dosing & Reconstitution Guide

Histrelin is administered via subcutaneous implant, typically placed in the inner upper arm. The dosing frequency for replacement is every 12 months. Two formulations are available: Vantas, which provides a 50 mg implant with an approximate daily release rate of 50 mcg, and Supprelin LA, also a 50 mg implant, but with a slightly higher release rate of about 65 mcg per day. The choice between these formulations may depend on specific research objectives and the desired release profile.

The onset of hormonal suppression following Histrelin implantation is generally observed within 2 to 4 weeks, reflecting the time required for the peptide to exert its effects. The half-life of the peptide itself is approximately 4 hours, while the implant is designed for a sustained release over a 12-month period. Steady-state concentrations are typically achieved within 4 weeks of implantation, with hormonal suppression effects becoming apparent in the same timeframe. Upon removal of the implant, the washout process is gradual, allowing for a controlled return to baseline hormonal levels.

For optimal preservation, lyophilized Histrelin should be stored refrigerated at temperatures between 2-8 °C (36-46 °F) and protected from light to prevent degradation. It is important to note that once reconstituted, Histrelin is not applicable in this context, as it is provided as a pre-formed implant. Ensuring proper storage conditions is essential to maintain the integrity and efficacy of the compound for research applications.

Research indicates that implant site reactions can occur in a small percentage of subjects, with reported incidences of pain, bruising, soreness, and erythema at the insertion site observed in up to 6% of cases. Additionally, systemic effects such as hot flashes have been noted in approximately 66% of prostate cancer patients undergoing treatment. Fatigue and headache are also common adverse effects. Contraindications include pregnancy, classified as Category X, and hypersensitivity to GnRH, GnRH agonists, or any components of the implant material. Special caution is advised for women who are pregnant or may become pregnant while using Histrelin.